Cargando…
Oxaliplatin plus S-1 or capecitabine as neoadjuvant or adjuvant chemotherapy for locally advanced gastric cancer with D2 lymphadenectomy: 5-year follow-up results of a phase II−III randomized trial
OBJECTIVE: To compare the effect of neoadjuvant chemotherapy (NACT) with adjuvant chemotherapy (ACT) using oxaliplatin plus S-1 (SOX) or capecitabine (CapeOX) on gastric cancer patients with D2 lymphadenectomy. METHODS: This was a two-by-two factorial randomized phase II−III trial, and registered on...
Autores principales: | Xue, Kan, Ying, Xiangji, Bu, Zhaode, Wu, Aiwen, Li, Zhongwu, Tang, Lei, Zhang, Lianhai, Zhang, Yan, Li, Ziyu, Ji, Jiafu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6232367/ https://www.ncbi.nlm.nih.gov/pubmed/30510363 http://dx.doi.org/10.21147/j.issn.1000-9604.2018.05.05 |
Ejemplares similares
-
The clinical value and usage of inflammatory and nutritional markers in survival prediction for gastric cancer patients with neoadjuvant chemotherapy and D2 lymphadenectomy
por: Li, Ziyu, et al.
Publicado: (2020) -
ABCC2-24C > T polymorphism is associated with the response to platinum/5-Fu-based neoadjuvant chemotherapy and better clinical outcomes in advanced gastric cancer patients
por: Li, Ziyu, et al.
Publicado: (2016) -
Impact of postoperative major complications on long-term survival after radical resection of gastric cancer
por: Yuan, Peng, et al.
Publicado: (2019) -
Up-Regulation of SALL4 Is Associated With Survival and Progression via Putative WNT Pathway in Gastric Cancer
por: Yang, Yang, et al.
Publicado: (2021) -
Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer
por: Eggington, S, et al.
Publicado: (2006)